These authors contributed equally to this manuscript.
Article first published online: 17 DEC 2010
Copyright © 2010 American Association for the Study of Liver Diseases
Volume 53, Issue 2, pages 618–627, February 2011
How to Cite
Moniaux, N., Song, H., Darnaud, M., Garbin, K., Gigou, M., Mitchell, C., Samuel, D., Jamot, L., Amouyal, P., Amouyal, G., Bréchot, C. and Faivre, J. (2011), Human hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein cures fas-induced acute liver failure in mice by attenuating free-radical damage in injured livers. Hepatology, 53: 618–627. doi: 10.1002/hep.24087
Potential conflict of interest: Nicolas Moniaux, Haiyan Song, Marion Darnaud, Kévin Garbin, Michelle Gigou, Claudia Mitchell, and Didier Samuel have no potential conflict of interest. Laure Jamot is an employee of Alfact Innovation. Paul Amouyal is Chairman of Alfact Innovation. Gilles Amouyal is CEO of Alfact Innovation. Christian Brechot is Vice-President at Mérieux Alliance. Jamila Faivre is a scientific consultant to Alfact Innovation.
J.F. received grant support from the Agence Nationale pour la Recherche (ANR-05-EMPB-005-02 and RPV07137LS), the Fondation de l'Avenir pour la Recherche Médicale Appliquée (ET7-473), the Association Française pour l'Etude du Foie (RAK08120LLA), and the Programme National de Recherche en Hépato-Gastroentérologie Inserm/AFEF (ASE07127LSA). N.M. was supported by grants from the Institut National de la Santé et la Recherche Médicale (INSERM) and the Institut National contre le Cancer (INCA).
- Issue published online: 27 JAN 2011
- Article first published online: 17 DEC 2010
- Accepted manuscript online: 19 NOV 2010 12:06PM EST
- Manuscript Accepted: 9 NOV 2010
- Manuscript Received: 30 JUL 2010
Acute liver failure (ALF) is a rare syndrome with a difficult clinical management and a high mortality rate. During ALF, several molecular pathways governing oxidative stress and apoptosis are activated to induce massive tissue injury and suppress cell proliferation. There are few anti-ALF drug candidates, among which is the C-type lectin Reg3α, or human hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein (HIP/PAP), which displayed promising properties for tissue regeneration and protection against cellular stress in transgenic mice. We report on substantial preclinical and clinical advances in the development of a recombinant (rc) full-length human HIP/PAP protein as an anti-ALF drug. The curative effects and mechanisms of action of rcHIP/PAP were investigated in murine Fas-induced ALF. Primary hepatocytes were cultured with cytotoxic doses of tumor necrosis factor α/actinomycin-D, transforming growth factor β, agonistic Fas antibody or hydrogen peroxide, and various concentrations of rcHIP/PAP. Cell viability, proliferation index, apoptosis, and oxidation were monitored. We found that rcHIP/PAP significantly improved survival in Fas-intoxicated mice in a dose-dependent and time-dependent manner, with optimum effects when it was injected at advanced stages of ALF. Primary hepatocytes were efficiently protected against multiple cell death signals by rcHIP/PAP. This survival benefit was linked to a depletion of oxidized biomolecules in injured liver cells due to a strong reactive oxygen species scavenging activity of rcHIP/PAP. Clinically, an escalating dose phase 1 trial demonstrated a good tolerability and pharmacokinetic profile of rcHIP/PAP in healthy subjects. Conclusion: The rcHIP/PAP protein exhibited significant curative properties against ALF in mice. It is a free-radical scavenger that targets a broad spectrum of death effectors and favors liver regeneration. The good safety profile of rcHIP/PAP during a phase 1 trial encourages evaluation of its efficacy in patients with ALF. (HEPATOLOGY 2011:53:618-627)